350096 Aggregation Studies of Beta-Amyloid Using Peptoids

Monday, November 4, 2013
Grand Ballroom B (Hilton)
Omkar Bhave1, Shannon L. Servoss1, Philip Turner1 and Melissa A. Moss2, (1)Chemical Engineering, University of Arkansas, Fayetteville, AR, (2)Dept. of Chemical Engineering, University of South Carolina, Columbia, SC

Over 35 million people all over the world suffer from Alzheimer’s disease (AD), the most common form

of dementia. AD is a neurological degenerative disease that is characterized by plaque formation of

Amyloid beta. The aggregation of the protein Amyloid beta is associated with the plaque formation in

between the nerve cell cavities, which leads to the death of neurons. There is no current medication

that has effectively cured AD; however, research has proven that there are some selective molecules

that prevent the aggregation of amyloid beta. We have synthesized a new peptoid called AB1 which is

derived from the Tjernberg peptide sequence. AB1 has shown promising results in inhibition of oligomer

formation of amyloid beta (1-40). Preliminary results have shown that the novel peptoid AB1 inhibited

fibrils formation by up to 84 percent as compared to the previous 44 percent from other peptoids.

Extended Abstract: File Not Uploaded